Sustanon 250
Blend of four testosterone esters with staggered release, from fast-acting propionate to slow decanoate.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Sustanon 250
Blend of four testosterone esters with staggered release, from fast-acting propionate to slow decanoate.
Evidence category: Reference only. This describes the source category, not approval or certainty.
Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.
Sustanon is a brand name for a mixed testosterone ester preparation given by intramuscular injection. A reference page on testosterone isocaproate lists it as one component of these mixed preparations and describes their action as longer than single short esters. The other link is a private clinic's guide to testosterone therapy, not a regulator document. No approving regulator label is cited here, so this rests on general reference material only.
Benefits reported in the imported source
- Reference material describes mixed testosterone esters as acting longer than single short esters
Risks and limits
- No approving regulator label is cited here, only a reference page and a private clinic's guide
- No trial evidence for this preparation appears in these sources
Source bottom line: A mixed testosterone ester covered here by general reference material, with no regulator label or trial.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
No study protocol recorded in this snapshot. This does not establish that no study exists.
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — Sustanon 250 Cycle Guide — Dosage, Protocol & PCT
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: Community consensus dosing for Sustanon 250 centers on 300–500 mg per week for entry-level cycles, administered in twice-weekly (Monday/Thursday) splits, with more advanced protocols using every-3-day or every-other-day injection frequencies to achieve flatter hormone curves.
Pharmacokinetic context
Historical half-life estimate: 24–504 hours. Four esters; blended release Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.
Source references
- Sustanon: HRT Guide for Trans Men & Non-Binary People
- Testosterone isocaproate - Wikipedia
- EMA: product information
Snapshot provenance
Source ID: catalog:hormone:sustanon-250. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.